Contraception
Volume 74, Issue 1 , Pages 31-35 , July 2006

Studies on uterine contractility following mifepristone and various routes of misoprostol

Received 10 February 2006 ,Revised 8 March 2006 ,Accepted 8 March 2006.

References 

  1. Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol. 1973;115:759–765
  2. Csapo AI. Prostaglandin impact inverted question mark for menstrual induction. Popul Rep G. 1974;(4):33–40
  3. Swahn ML, Bygdeman M. Medical methods to terminate early pregnancy. In:  Bygdeman M editors. Baillière's clinical obstetrics and gynecology. Vol. 4 (2):London: Baillière Tindall; 1990;p. 293–306
  4. Herrman W, Wyss R, Riondel A, et al. Effect d'un steroid anti-progesteron chez la femme; interruption du cycle menstruel et de la grossess au debut. C R Acad Sci (Paris). 1982;294:933–939
  5. Kovacs L, Sas M, Resch BA, et al. Termination of early pregnancy by RU 486 — an antiprogestional compound. Contraception. 1984;29:399–410
  6. Van Look PFA, Bygdeman M. Antiprogestational steroids: a new dimension in human fertility regulation. In:  Mulligan SR editors. Oxford reviews of reproductive biology. England: Oxford; 1989;p. 1–60
  7. Bygdeman M, Swahn ML. Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception. 1985;32:45–51
  8. Swahn ML, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynaecol. 1988;95:126–134
  9. Garfield RE, Blennerhasset Miller SM. Control of myometrial contractility: role and regulation of gap junctions. Oxf Rev Reprod Biol. 1988;10:436–490
  10. Norman JE, Thong KJ, Baird DT. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet. 1991;338:1233–1236
  11. Cameron IT, Michie AF, Baird DT. Therapeutic abortion in early pregnancy with antiprogestogen RU 486 alone or in combination with a prostaglandin analogue (gemeprost). Contraception. 1986;34:459–468
  12. Ulmann A, Silvestre L, Chenama L, et al. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Acta Obstet Gynecol Scand. 1992;71:278–283
  13. UK Multicentre Trial . The efficacy and tolerance of mifepristone and prostaglandin in first trimester of pregnancy. Br J Obstet Gynaecol. 1990;97:480–486
  14. World Health Organization . Termination of pregnancy with reduced doses of mifepristone. Br Med J. 1993;307:532–537
  15. Norman JE, Kelly RW, Baird DT. Uterine activity and decidual prostaglandin production in women in early pregnancy in response to mifepristone with or without indomethacin in vivo. Hum Reprod. 1991;6:740–744
  16. Peyron R, Aubény E, Targosz V, et al. Early pregnancy interruption with RU 486 (mifepristone) and misoprostol, an orally active prostaglandin analogue. N Engl J Med. 1993;328:1509–1513
  17. El-Refaey H, Rajasekar D, Abdotta M, et al. Induction of abortion with mifepristone (RU 486) and oral and vaginal misoprostol. N Engl J Med. 1995;332:983–987
  18. McKinley C, Joo Thong K, Baird DT. The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum Reprod. 1993;8:1502–1505
  19. von Hertzen H, Honkanen H, Piaggio G, et al. WHO Research Group on Post-Ovulatory Methods for Fertility Regulation. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. Part 1: efficacy. BJOG. 2003;110:808–818
  20. Zieman M, Fong SK, Benowitz NL, et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90:88–92
  21. Tang OS, Schweer H, Seyberth HW, et al. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod. 2002;17:332–336
  22. Gemzell-Danielsson K, Marions L, Rodriguez A, et al. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynecol. 1999;93:275–280
  23. Caldeyro-Barcia R, Poserro JJ. Oxytocin and contractility of the human pregnant uterus. Ann N Y Acad Sci. 1959;75:813–830
  24. Ho PC, Ngai SW, Liu KL, et al. Vaginal misoprostol compared with oral misoprostol in termination of second trimester pregnancy. Obstet Gynecol. 1997;90:735–738
  25. Tang OS, Ho PC. Pilot study on the use of sublingual misoprostol for medical abortion. Contraception. 2001;64:315–317
  26. Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. Hum Reprod. 2004;19:81–84
  27. Tang OS, Lau WN, Chan CC, Ho PC. A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG. 2004;111:1001–1005
  28. Schaff EA, Fielding SL, Westhoff C, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA. 2000;284:1948–1953
  29. Creinin MD, Fox MC, Teal S, et al. MOD Study Trial Group. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol. 2004;103(5 Pt 1):851–859
  30. Winikoff B. Acceptability of medical abortion in early pregnancy. Fam Plann Perspect. 1995;185:142–148
  31. Bygdeman M, Christensen NJ, Dimov V, et al. Termination of pregnancy by a slow release device containing 16, 16-dimethyl-trans-delta 2 PGE1 methyl ester. Asia Oceania J Obstet Gynaecol. 1984;10:359–365
  32. Cameron IT, Baird DT. A controlled release form of 16,16-dimethyl-trans-delta 2-PGE, methyl ester for early abortion. Contraception. 1986;33:121–125
  33. Fiala C, Aronsson A, Stephansson O, Hellborg M, Gemzell-Danielsson K. Effects of slow release misoprostol on uterine contractility in early pregnancy. Hum Reprod. 2005;20:2648–2652[Electronic publication, 2005 May 26]

PII: S0010-7824(06)00079-5

doi: 10.1016/j.contraception.2006.03.009

Contraception
Volume 74, Issue 1 , Pages 31-35 , July 2006

Article Tools

* Image Usage & Resolution